Literature DB >> 17200437

Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors.

William B Campbell1, John R Falck.   

Abstract

The endothelium regulates vascular tone through the release of a number of soluble mediators, including NO, prostaglandin I2, and endothelium-derived hyperpolarizing factor. Epoxyeicosatrienoic acids are cytochrome P450 epoxygenase metabolites of arachidonic acid. They are synthesized by the vascular endothelium and open calcium-activated potassium channels, hyperpolarize the membrane, and relax vascular smooth muscle. Endothelium-dependent relaxations to acetylcholine, bradykinin, and shear stress that are not inhibited by cyclooxygenase and NO synthase inhibitors are mediated by the endothelium-derived hyperpolarizing factor. In arteries from experimental animals and humans, the non-NO, non-prostaglandin-mediated relaxations and endothelium-dependent hyperpolarizations are blocked by cytochrome P450 inhibitors, calcium-activated potassium channel blockers, and epoxyeicosatrienoic acid antagonists. Acetylcholine and bradykinin stimulate epoxyeicosatrienoic acid release from endothelial cells and arteries. These findings indicate that epoxyeicosatrienoic acids act as endothelium-derived hyperpolarizing factors and regulate arterial tone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200437     DOI: 10.1161/01.HYP.0000255173.50317.fc

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  88 in total

Review 1.  Cell signaling of angiotensin II on vascular tone: novel mechanisms.

Authors:  Aurelie Nguyen Dinh Cat; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 2.  Role of reactive oxygen and nitrogen species in the vascular responses to inflammation.

Authors:  Peter R Kvietys; D Neil Granger
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

Review 3.  Endothelial dysfunction in diabetes: multiple targets for treatment.

Authors:  Hong Ding; Chris R Triggle
Journal:  Pflugers Arch       Date:  2010-03-18       Impact factor: 3.657

4.  11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries.

Authors:  Ishfaq A Bukhari; Abdul Jabbar Shah; Kathryn M Gauthier; Katherine A Walsh; Sreenivasulu Reddy Koduru; John D Imig; John R Falck; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 5.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 6.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

7.  Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.

Authors:  Jafar Sadik B Shaik; Muzamil Ahmad; Wenjin Li; Marie E Rose; Lesley M Foley; T Kevin Hitchens; Steven H Graham; Sung Hee Hwang; Bruce D Hammock; Samuel M Poloyac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

Review 8.  Arachidonic acid cytochrome P450 epoxygenase pathway.

Authors:  Arthur A Spector
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

9.  Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Authors:  Kimberly L Fife; Yingmei Liu; Kara R Schmelzer; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bruce D Hammock; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-09-24       Impact factor: 4.030

Review 10.  Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.

Authors:  Ralf Köhler; Brajesh P Kaistha; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2010-02       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.